This article was originally published in The Rose Sheet
Executive SummaryThe National Advertising Division of the Council of Better Business Bureaus recommends Modern Health Labs modify or discontinue ad claims in an infomercial and Web site for its Scalp Med hair re-growth product because the five statements reviewed in the case were either not supported by evidence or could confuse customers, agency reports. NAD further recommends the advertiser disclose in ads that the principal hair growth ingredient in its product is FDA-approved minoxidil. The case was brought to NAD's attention by competitor Global Vision Products...
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.